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To the Editor, 1 
on February 21st, 2020, the first case of SARS-CoV-2 transmission within the Italian borders, with 2 
no apparent link with imported cases, was reported (1). The number of confirmed infections has 3 
therefore multiplied, and Italy is currently the second European country by number of recorded 4 
cases, with Lombardy, the most affected region (2). The regional health service has been 5 
reorganized, and COVID-19 units have rapidly been developed in most regional hospitals (3). 6 
COVID-19 outbreak also represents a significant challenge for the organization of translational 7 
research activity in a coordinated and multi-disciplinary approach. 8 
Founded in the XV century, the Ospedale Maggiore Policlinico in Milan, Italy, is one of the leading 9 
Italian hospital in clinical and research activities with 900 beds and 36,000 hospitalization per year. 10 
Notably, it hosts units for clinical follow up and translational research in pulmonary, 11 
haematological, infectious diseases, as well as a national reference centre for Extracorporeal 12 
membrane Oxygenation (ECMO). From 21th February 2020, to cope with the COVID-19 13 
emergency, the organization of the Hospital has been quickly modified and four different pavilions 14 
have been entirely dedicated to the management of COVID-19 patients to accommodate 350 15 
patients of which 50 in ICUs. 16 
In the ongoing COVID-19 pandemic, the central research governance of the Ospedale Maggiore 17 
Policlinico has faced several challenges arising from: (i) the emergence of many study proposals 18 
from different research groups, on the same patients; (ii) the need to coordinate ethical questions in 19 
the absence of standardized procedures and approved treatments; (iii) the need to collect 20 
biospecimens of interest for basic science and translational research projects; (iv) the need to divert 21 
staff from their normal research routines to COVID-19 focused projects, consistent with public 22 
health goals. 23 
Thus, our first action was to rapidly establish a COVID19 Research Steering Committee with the 24 
aims to guide Institutional research activities. 25 
 4
Subsequently, an Institutional Coronavirus Registry (“COVID-19 Network”), was established to 1 
answer present and future research questions regarding the epidemiology and clinical 2 
presentation/evolution of this disease (4) and set up a biobank of biological samples for translational 3 
studies (EC approval nr. 241_2020, 17th March 2020). Funding for the bio-banking activity was 4 
provided by Scientific Direction to the POLI-MI biobank, the Hospital central facility for 5 
collection, conservation and assignment of biological material. 6 
Aims of the registry are to: a) describe the epidemiological and clinical characteristics of patients 7 
admitted to the COVID-19 units; b) describe diagnostic and therapeutic interventions; c) evaluate 8 
the short- and long-term clinical outcomes and prognostic factors; d) allow subgroup analyses of 9 
specific patients’ groups. Moreover, biological samples (plasma, PBMCs and stool) are collected at 10 
time of diagnosis and at several timepoints and stored for future investigations. 11 
The registry includes all consecutive adults (aged 18 years or older) with a positive RT-PCR for 12 
SARS-CoV-2 at the time of admission to the Policlinico Hospital, with more than 800 patients 13 
expected to be enrolled.  14 
The response of our Hospital to COVID-19 outbreak was fast and well-structured in order to guide 15 
Institutional research activity on COVID19 in an integrated and multi-disciplinary basis. To this 16 
end, beyond the medical staff, 15 data managers, 1 biostatistician and 1 ethics were involved in this 17 
activity. So far, 103 studies in several patients’ groups are in different stages of development, 18 
among these 58 are observational, 19 non-pharmacological interventional and 6 pharmacological 19 
interventional studies. The Ethical Committee meets on a daily basis to rapidly assess the scientific 20 
and ethical value of studies. Moreover, we have opened the Registry to several Regional and 21 
National centers to allow collection of data also for centers with limited research resources, and to 22 
create a Network of different hospital units. To date, more than 984 patients overall have been 23 
enrolled (641 observed at the coordinating centre, Policlinico Hospital), and more than 1000 24 
biological samples have been stored. Moreover, researchers from this study group already produced 25 
112 papers on COVID-19 (currently in press or already published). 26 
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The COVID-19 network will also provide a platform for future national and international 1 
multicenter studies and investigator-initiated satellite projects: we are planning not only 2 
epidemiological studies, but also precision medicine studies with a multidisciplinary approach, 3 
including immunology, virology, and omics approaches. To the best of our knowledge, only 3 4 
others multi-centric registries are currently ongoing at a National level, focused on neonates, 5 
children and intensive-care units. 6 
Evaluating our experience as Reference Hospital facing COVID-19 epidemic, we think that the 7 
tools that have facilitated research activities have been: (i) strong leadership in different disciplines 8 
which proved fundamental in the management of COVID-19 patients; (ii)  IT resources, such as 9 
RedCap, i2b2, tele-conferencing systems; (iii) coordination between different research units; (iv) 10 
involvement of data manager and technical personnel dedicated to data collection, sample 11 
collection, processing and storage; v) collaboration with others Research Institutes and clinical 12 
centers; vi) strong motivation and altruism of both clinical, research and support staff.  13 
On the other hand, administrative issues linked to documents generation and approval often acted as 14 
barriers. Furthermore, limited data available in clinical electronic records required large human 15 
resources (data managers) to input high-granularity data. Finally, conducting interventional 16 
pharmacological studies proved difficult, owing to the limited preclinical and clinical data on many 17 
proposed drugs, and to centralization at national level of drug trials. 18 
To fully exploit the potential of our registry, data sharing will be crucial: consistently with similar 19 
initiatives at the national and international level, our data will be available for projects proposed by 20 
basic and clinical research groups worldwide.  21 
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